Scynexis Inc (SCYX) Files Form 4 Insider Buying : Clarence Patrick Machado Buys 20,000 Shares

Scynexis Inc (SCYX): Clarence Patrick Machado , director of Scynexis Inc purchased 20,000 shares on Jun 24, 2016. The Insider buying transaction was reported by the company on Jun 28, 2016 to the Securities and Exchange Commission. The shares were purchased at $2.39 per share for a total value of $47,800.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 27, 2016, Marco Taglietti (CEO) purchased 246 shares at $3.20 per share price.On May 27, 2016, Ann Hanham (director) purchased 4,225 shares at $3.64 per share price.Also, On Sep 18, 2015, Gonzalez David Angulo (Chief Medical Officer) purchased 3,000 shares at $7.00 per share price.

Shares of SCYNEXIS Inc (SCYX) ended Monday, Jun 27, 2016 session in red amid volatile trading. The shares closed down -0.07 points or -3.18% at $2.13 with 1,23,610 shares getting traded. Post opening the session at $2.2, the shares hit an intraday low of $2.08 and an intraday high of $2.2499 and the price vacillated in this range throughout the day. The company has a market cap of $30 M and the number of outstanding shares has been calculated to be 1,39,06,828 shares. The 52-week high of SCYNEXIS Inc is $9.25 and the 52-week low is $2.05.

SCYNEXIS Inc Money Flow Index Chart

SCYNEXIS Inc. is a pharmaceutical company. The Company is engaged in the discovery development and commercialization of anti-infectives. It also provides contract research and development services primarily in the field of animal health. Its lead product candidate SCY-078 is an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. SCY-078 has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species including drug resistant strains. In addition the Company has additional compounds similar to SCY-078. The Company has developed a platform for cyclophilin inhibitors. Its cyclophilin inhibitor platform has two clinical stage compounds: SCY-635 which is a cyclophilin inhibitor for the treatment of dog dry eye and SCY-641 which is a cyclophilin inhibitor with activity similar to cyclosporine for the treatment of viral diseases in humans.

Leave a Reply

SCYNEXIS Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on SCYNEXIS Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.